Post-IPO Debt - Evelo Biosciences
Investment Firm
Overview
Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.
Announced Date
Dec 16, 2022
Funding Type
Post Ipo Debt
Highlights
Location
United States, North America
Social
Participant Investors
1
| Investor Name |
|---|
 Horizon Technology Finance |
Round Details and Background
Evelo Biosciences raised $45000000 on 2022-12-16 in Post-IPO Debt
Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.
Company Funding History
8
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jul 10, 2023 |  Post-IPO Equity - Evelo Biosciences | - | 25.5M | |
| Jul 25, 2019 | Post-IPO Debt - Evelo Biosciences | 1 | - | 45.0M |
| Jul 11, 2017 | Series B - Evelo Biosciences | 5 | - | 50.0M |
| Nov 04, 2015 | Series A - Evelo Biosciences | 1 | - | 35.0M |
Recent Activity
There is no recent news or activity for this profile.